Assessment of the efficacy and safety of fampridine.

OBJECTIVE Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis. METHOD A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial. RESULTS Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects. CONCLUSIONS The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking.

[1]  A. H. Ledinek,et al.  Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients , 2015, Clinical Neurology and Neurosurgery.

[2]  André Thevenon,et al.  Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life , 2015, Journal of Neurology.

[3]  M. Castillo,et al.  Validez clínica de las variables cuantitativas de la marcha en pacientes con esclerosis múltiple. Comparativa entre el test de los 25 pies y el sistema electrónico de marcha GAITRite , 2014 .

[4]  H. Wiendl,et al.  Long-term effects of dalfampridine in patients with multiple sclerosis , 2014, Journal of the Neurological Sciences.

[5]  T. Berger,et al.  Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases , 2013, Patient related outcome measures.

[6]  Frances Lynn,et al.  Timed 25-Foot Walk , 2013, Neurology.

[7]  L. Krupp,et al.  A phase 3 trial of extended release oral dalfampridine in multiple sclerosis , 2010, Annals of neurology.

[8]  D. Cadavid,et al.  Sensibilidad de la escala ampliada del estado de discapacidad (EDSS) a la progresión de la enfermedad y la intervención terapéutica en las formas progresivas de la esclerosis múltiple , 2010 .

[9]  L. Krupp,et al.  Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.